What blood pressure target should be aimed for in patients with chronic kidney disease, including considerations for proteinuria and elderly or frail individuals?

Blood Pressure Goals in Chronic Kidney Disease

For patients with CKD and hypertension, target a systolic BP <120 mmHg using standardized office BP measurement when tolerated, as this reduces cardiovascular mortality and all-cause mortality. 1, 2, 3

Primary Recommendation Framework

The most recent and authoritative guidance comes from the 2024 ESC Guidelines 1 and 2024 KDIGO Guidelines 2, both recommending:

• Initial target: <140/90 mmHg for all CKD patients
• Optimal target: Systolic BP 130-139 mmHg range (ESC) or <120 mmHg (KDIGO) when tolerated
• Critical caveat: The <120 mmHg target applies ONLY to standardized office BP measurement, not routine office readings

Why Standardized BP Measurement Matters

Routine office BP measurements are unreliable and typically read 5-15 mmHg higher than standardized measurements 3. Applying intensive targets to routine measurements risks overtreatment with hypotension, falls, and acute kidney injury. If you cannot perform standardized BP measurement (automated, unattended readings after 5 minutes of rest), use the more conservative target of <130/80 mmHg 1, 4.

Specific Clinical Scenarios

Patients with Moderate-to-Severe Albuminuria (>30 mg/mmol or >300 mg/24h)

Target systolic BP 120-129 mmHg 1, 2

• These patients derive the greatest benefit from intensive BP control for both cardiovascular protection and slowing CKD progression 5, 6
• Use ACE inhibitor or ARB as first-line therapy (mandatory for albuminuria >300 mg/24h) 2
• The 2009 Canadian guidelines recommended <130/80 mmHg specifically for proteinuric CKD 7, but newer evidence supports even lower targets

Patients WITHOUT Significant Albuminuria

Target <140/90 mmHg, or 130-139 mmHg if tolerated 1, 5

• Less aggressive targets are appropriate as cardiovascular benefit is the primary concern, not renal progression
• The evidence for intensive BP lowering in non-proteinuric CKD is weaker 6

Advanced CKD (eGFR <30 mL/min/1.73m²)

Target systolic BP 120-129 mmHg if eGFR >30; individualize if eGFR <30 1

• Monitor closely for hyperkalemia, acute kidney injury, and electrolyte disturbances
• The 2020 Hypertension Canada guidelines note that patients meeting SPRINT criteria (age >50, elevated CV risk) should target <120 mmHg even with moderate CKD 4

Elderly or Frail Patients (≥80 years)

Target 130-139 mmHg systolic 1

• Avoid targeting <120 mmHg in frail patients, those with high fall risk, limited life expectancy, or symptomatic orthostatic hypotension 2
• The 2014 guidelines review showed most international guidelines recommended <150/90 mmHg for patients ≥80 years 8, but this has been superseded by newer evidence suggesting lower targets are safe in healthy elderly

Patients with Diabetes and CKD

Target <130/80 mmHg 1, 4

• The 2024 ESC guidelines recommend treating to systolic BP 130 mmHg and <130 mmHg if tolerated, but not <120 mmHg 1
• For elderly diabetics (≥65 years), target 130-139 mmHg systolic 1
• Use ACE inhibitor or ARB for any degree of albuminuria 2

Polycystic Kidney Disease

Target <110 mmHg systolic (measured by home BP monitoring) 4

• Based on HALT-PKD trial showing slower kidney volume growth and reduced cardiovascular hypertrophy
• This is a unique exception requiring more intensive control

Medication Strategy

First-line agents:

• ACE inhibitor or ARB (required for albuminuria ≥30 mg/mmol) 2
• Add CCB or thiazide/thiazide-like diuretic as second agent 1, 4
• Use single-pill combinations to improve adherence 1

Key warnings:

• Never combine ACE inhibitor + ARB (increases harm without benefit) 7, 4, 7, 4
• Monitor creatinine and potassium 2-4 weeks after starting or increasing RAS inhibitors 2
• Use loop diuretics instead of thiazides when eGFR <30 mL/min/1.73m² 7

Common Pitfalls to Avoid

1. Applying intensive targets to routine office BP measurements - This causes overtreatment. Either use standardized measurement or more conservative targets 3

2. Stopping RAS inhibitors for small creatinine increases - Up to 30% increase in creatinine is acceptable and expected when starting these medications 2

3. Using the same target for all CKD patients - Albuminuria status fundamentally changes the risk-benefit calculation 6

4. Ignoring diastolic BP - Target diastolic 70-79 mmHg; avoid <70 mmHg as this may increase cardiovascular risk 1

Evidence Quality and Controversies

The recommendation for <120 mmHg is based primarily on SPRINT trial data, which showed clear cardiovascular and mortality benefits 3. However, SPRINT did not show benefit for preventing CKD progression and raised concerns about increased acute kidney injury 9, 10.

A 2024 Cochrane review found that lower BP targets (≤135/85 mmHg) versus standard targets (≤140/90 mmHg) resulted in little to no difference in mortality, cardiovascular events, or progression to end-stage renal disease, with potential increases in serious adverse events 10. This highlights the importance of individualization, particularly in patients without significant albuminuria.

The divergence between KDIGO (<120 mmHg) and ESC (130-139 mmHg range) reflects ongoing uncertainty, with ESC taking a more conservative stance given concerns about adverse events and the requirement for standardized measurement 11, 9.